Showing results 1 to 20 of 24
next >
| Issue Date | Title | Author(s) |
| 13-May-2020 | Anticancer drug R&D landscape in China | Zhao, Shen; Zhao, Hongyun; Lv, Cheng; Gong, Jifang; Zhang, Jian; Fang, Wenfeng; Li, Jin; Hu, Xichun; Ba, Yi; Xu, Binghe; Zhang, Yanqiao; Fan, Yun; Li, Kunyan; Chen, Xiaoyuan; Yang, Zhimin; Shen, Lin; Zhang, Li |
| 2019 | Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study | Zhu, Anjie; Yuan, Peng; Wang, Jiayu; Fan, Ying; Luo, Yang; Cai, Ruigang; Zhang, Pin; Li, Qing; Ma, Fei; Xu, Binghe |
| 2-Nov-2022 | Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer | Mo, Hongnan; Yan, Xiaoyan; Zhao, Fang; Teng, Yuee; Sun, Xiaoying; Lv, Zheng; Cao, Mengru; Zhao, Jiuda; Song, Guohong; Pan, Bo; Li, Huihui; Zhai, Jingtong; Xu, Binghe; Ma, Fei |
| 2018 | Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2-advanced breast cancer (ABC) in Chinese women | Xu, Binghe; Zhang, Qingyuan; Li, Huiping; Sun, Wan; Li, Wei; Wang, Shusen; Liao, Ning; Shen, Peng; Shao, Bin; Zhao, Wenhui; Liu, Yuan; Li, Vincent; Linn, Carlos; Yan, Ping; Plotka, Anna; Jiang, John; Wang, Diane D. |
| 2014 | Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel | Li, Qian; Liu, Mei; Ma, Fei; Luo, Yang; Cai, Ruigang; Wang, Liming; Xu, Ningzhi; Xu, Binghe |
| Aug-2021 | Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators A Phase 2 Randomized Clinical Trial | Fan, Ying; Sun, Tao; Shao, Zhimin; Zhang, Qingyuan; Ouyang, Quchang; Tong, Zhongsheng; Wang, Shusen; Luo, Yang; Teng, Yuee; Wang, Xiaojia; Wang, Shu; Liu, Qiang; Feng, Jifeng; Shen, Kunwei; Song, Yanqiu; Wang, Jiayu; Ma, Fei; Li, Qing; Zhang, Pin; Xu, Binghe |
| 2015 | Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial | Huang, Liang; Chen, Sheng; Yang, Wentao; Xu, Binghe; Huang, Tao; Yang, Hongjian; Zheng, Hong; Wang, Yongsheng; Song, Erwei; Zhang, Jin; Cui, Shude; Pang, Da; Tang, Lili; Lei, Yutao; Geng, Cuizhi; Shao, Zhiming |
| 20-May-2021 | Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial. | Zheng, Fangchao; Du, Feng; Wang, Yongsheng; Wang, Xue; Wang, Jiayu; Yue, Jian; Ma, Fei; Fan, Ying; Xu, Binghe; Yuan, Peng |
| Feb-2020 | Everolimus in first-line treatment of advanced premenopausal breast cancer: Results from MIRACLE (everoliMus trIal foR AdvanCed premenopausaL brEast cancer) study | Fan, Ying; Sun, Tao; Shao, Zhimin; Zhang, Qingyuan; Ouyang, Quchang; Tong, Zhongsheng; Wang, Shusen; Luo, Yang; Teng, Yuee; Wang, Xiaojia; Wang, Shu; Liu, Qiang; Feng, Jifeng; Shen, Kunwei; Song, Yanqiu; Wang, Jiayu; Ma, Fei; Li, Qing; Zhang, Pin; Xu, Binghe |
| 20-May-2021 | The intra-tumor heterogeneity of ER and HER2 expression in patients with ER-positive and HER2-positive breast cancer. | Ju, Jie; Du, Feng; Gao, Songlin; Si, Yiran; Hu, Nanlin; Liu, Dongxu; Wang, Xue; Yue, Jian; Zheng, Fangchao; Kang, Yikun; Yang, Zixuan; Ma, Fei; Xu, Binghe; Yuan, Peng |
| 2015 | National consensus in China on diagnosis and treatment of patients with advanced breast cancer | Xu, Binghe; Hu, Xichun; Jiang, Zefei; Li, Huiping; Chen, Jiayi; Cui, Shude; Li, Qing; Liao, Ning; Liu, Donggeng; Liu, Jian; Lu, Jinsong; Shen, Kunwei; Sun, Tao; Teng, Yuee; Tong, Zhongsheng; Wang, Shulian; Wang, Xiang; Wang, Xiaojia; Wang, Yongsheng; Wu, Jiong; Yuan, Peng; Zhang, Pin; Zhang, Qingyuan; Zheng, Hong; Pang, Da; Ren, Guosheng; Shao, Zhimin; Shen, Zhenzhou; Song, Erwei; Song, Santai |
| 2017 | Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study | Li, Huiping; Zhang, Qingyuan; Li, Wei; Wang, Shusen; Liao, Ning; Shen, Peng; Shao, Bin; Zhao, Wenhui; Sun, Wan; Yan, Ping; Wang, Diane; Li, Vince; Linn, Carlos; Shi, Haihong; O'Gorman, Melissa; Xu, Binghe |
| Apr-2021 | Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2-advanced breast cancer in Chinese women | Xu, Binghe; Li, Huiping; Zhang, Qingyuan; Sun, Wan; Yu, Yanke; Li, Wei; Wang, Shusen; Liao, Ning; Shen, Peng; Liu, Yuan; Huang, Yaling; Linn, Carlos; Zhao, Huadong; Jiang, John; Wang, Diane |
| Jul-2021 | Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer | Wang, Jiani; Zhang, Qingyuan; Li, Qiao; Mu, Yuxin; Jing, Jing; Li, Huiping; Li, Wei; Wang, Jingfen; Yu, Guohua; Wang, Xian; Ouyang, Quchang; Hao, Jing; Lu, Liang; Zhou, Li; Guan, Jin; Li, Qing; Xu, Binghe |
| 2016 | Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients | Zhang, Pin; Tong, Zhongsheng; Tian, Fuguo; Wang, Yongsheng; Yang, Junlan; Li, Weilian; Di, Lijun; Liu, Wei; Tang, Li; Qiu, Rongguo; Xu, Binghe |
| 15-Feb-2021 | A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer | Hu, Nanlin; Zhu, Anjie; Si, Yiran; Yue, Jian; Wang, Xue; Wang, Jiayu; Ma, Fei; Xu, Binghe; Yuan, Peng |
| Apr-2024 | Practice guideline on ovarian tissue cryopreservation and transplantation in the prevention and treatment of iatrogenic premature ovarian insufficiency | Ruan, Xiangyan; Xu, Che; Huang, Hefeng; Xu, Binghe; Du, Juan; Cheng, Jiaojiao; Jin, Fengyu; Gu, Muqing; Kong, Weimin; Yin, Chenghong; Wu, Yurui; Tian, Qinjie; Cao, Yunxia; Wu, Ruifang; Xu, Liangzhi; Jin, Jing; Li, Yanglu; Dai, Yinmei; Ju, Rui; Ma, Fei; Wang, Gang; Wei, Wei; Huang, Xiaojun; Qin, Maoquan; Lin, Yuan; Sun, Yuan; Liu, Rong; Zhang, Wei; Li, Xiaodong; Zou, Lin; Hao, Min; Ye, Xiyang; Wang, Fuling; Wang, Yue; Hu, Zhuoying; Huang, Yanhong; Zhu, Tianyuan; Yang, Caihong; Wang, Jinping; Yang, Xiaomin; Ni, Rong; Wang, Liqun; Luo, Guangxia; Min, Aiping; Zhang, Siyou; Li, Peiling; Cheng, Linghui; Li, Lianfang; Jin, Quanfang; Shi, Dongmei; Li, Yan; Ren, Fangying; Cheng, Yanxiang; Niu, Jumin; Tian, Ying; Mueck, Alfred O. |
| 2019 | Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study | Ma, Fei; Ouyang, Quchang; Li, Wei; Jiang, Zefei; Tong, Zhongsheng; Liu, Yunjiang; Li, Huiping; Yu, Shiying; Feng, Jifeng; Wang, Shusen; Hu, Xichun; Zou, Jianjun; Zhu, Xiaoyu; Xu, Binghe |
| 20-May-2020 | Pyrotinib or lapatinib plus capecitabine for HER2+metastatic breast cancer (PHOEBE): A randomized phase Ill trial. | Xu, Binghe; Yan, Min; Ma, Fei; Hu, Xi-Chun; Feng, Ji Feng; Ouyang, Quchang; Tong, Zhongsheng; Li, Huiping; Zhang, Qingyuan; Sun, Tao; Wang, Xian; Yin, Yongmei; Cheng, Ying; Li, Wei; Zhu, Xiaoyu; Chen, Chunxia; Zou, Jianjun |
| 2018 | A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab | Xu, Binghe; Ma, Fei; Ouyang, Quchang; Li, Wei; Jiang, Zefei; Tong, Zhongsheng; Liu, Yunjiang; Li, Huiping; Yu, Shiying; Feng, Jifeng; Wang, Shusen; Hu, Xichun; Zhu, Xiaoyu; Zou, Jianjun |
